 |
|
|
|
|
| |
 |
|
|
| |
Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies. |
|
| |
|
|
| |
| |
|
| |
|
|
Collegium Pharmaceutical, Inc.
400 Highland Corporate Drive
Cumberland, RI 02864
Phone: 401.762.2000
|
|
| |
| |
Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. Collegium's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products.
The company will apply its licensing and formulations capabilities to extend the market exclusivity of or improve the performance of pharmaceuticals whose patents are about to expire. Improved bioavailability and reduced dosing frequency for drugs in general, and reduced abuse potential for opioids are targeted. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas.
|
|
| |
|
| Millennia Team |
Dana Callow,
Pat Fortune, Ph.D.
|
|
| Visit the Website |
http://www.collegiumpharma.com |
|
| Case Study |
Collegium Pharmaceuticals is a developer of late stage specialty pharmaceutical products derived from approved or about to be approved chemical entities. The company was founded by the team that also founded Copley Pharmaceuticals, a highly successful generic pharmaceutical company. The company’s management is highly experienced in drug formulation techniques and drug delivery, and, as such, are positioned to exploit profitable niches in the pharmaceutical market. Collegium applies proprietary formulation techniques to produce products with improved therapeutic performance. This may involve, for example, combining two different drugs into a single formulation in which the delivery and absorption of the two components is controlled to produce a therapeutic effect. Collegium creates value through performing internal “proof of concept” and out-licensing to suitable marketing partners or in certain cases obtaining regulatory approval and marketing the products themselves. For approved chemical entities, the Company uses regulatory paths that do not require large clinical trials to gain approval. In this way, the cost, time and risk associated with clinical trials is avoided, even as valuable intellectual property rights are maintained. The company already has developed or in-licensed multiple proprietary formulation and drug delivery platforms that are applicable both to new drugs and drugs about to come off patent. Thus, the company’s products and services enable pharmaceutical and biotech companies to improve performance of their products and extend patent lives. At the same time, they enable generic pharmaceutical companies to enhance financial performance by marketing proprietary formulations.
|
|
| Related News |
Cumberland, RI - January 8, 2009
Collegium Pharmaceutical Announces FDA Approval of AllerNaze™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
Cumberland, RI - July 16, 2008
Collegium Pharmaceutical Announces U.S. Patent Issued Covering its DETERx™ Abuse Deterrent Sustained Release Technology
Cumberland, RI - July 15, 2008
Collegium Pharmaceutical Announces Completion of Series D Financing
Cumberland, RI - December 6, 2007
Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts
Cumberland, RI - October 31, 2007
Collegium Pharmaceutical Inc. Announces Successful Completion of Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
Cumberland, RI - August 15, 2007
Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis
Cumberland, RI - July 12, 2007
Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
Cumberland, RI - March 5, 2007
Collegium Announces Successful Completion of Allergic Rhinitis Product Trial
Cumberland, RI - October 4, 2006
Collegium Pharmaceutical Inc., Announces FDA Acceptance of IND for Novel Combination Allergic Rhinitis Product
Cumberland, RI - June 6, 2006
Collegium Pharmaceutical Announces the Achievement of Development Milestone Under the Agreement with Cypress Bioscience
Tampa, FL. - December 6, 2005
Accentia Biopharmaceuticals Acquires Exclusive License for an Additional Late-Stage Respiratory Product
Cumberland, RI - August 25, 2005
BTG and Collegium Pharmaceutical to Develop a Modified Release Asthma Product
Cumberland, RI - July 26, 2005
Collegium Pharmaceutical Inc., Announces the Launch of Exactacain™
Cumberland, RI - (BUSINESS WIRE) - April 20, 2005
Collegium Pharmaceutical Inc. and United Research Laboratories/Mutual Pharmaceutical Company Announce Product Development Agreement
Cumberland, RI - (BUSINESS WIRE) - January 4, 2005
Collegium Pharmaceutical Inc., HEALTHPOINT, Ltd Announce Licensing Agreement for Two Late Stage Products
Cumberland, RI - (BUSINESS WIRE) - June 17, 2004
Collegium Pharmaceutical Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for Novel Anti-Histamine Combination
Cumberland, RI - (BUSINESS WIRE) - December 3, 2003
Collegium Pharmaceutical Signs Agreement with Endo Pharmaceuticals to Develop Abuse Deterrent Pain Products
Cumberland, RI - October 28, 2003
Collegium Pharmaceutical raises Series A funding from Boston Millennia Partners
|
|
|
|
|
|
|
|
|
|
